Pfizer and partner BioNTech have startedtesting a COVID-19 vaccinethat specifically targets theomicron variant, the companies said Tuesday.
One day later, Moderna also announced the start of a clinical trial tostudy its omicron-specific booster.
Jansen added that developing and investigating variant-based vaccines is “essential in our efforts towards this goal.”
Pfizer’s trial includes up to 1,420 adults in three groups.
People in the different groups will get a different number of doses of Pfizer’s omicron-focused vaccine.
Moderna’s study will include about 600 participants.
And recent data shows just how well that’s working.
